ODs reach for artificial tears first to treat dry eye

Article

In a poll fielded on the Optometry Times website, we asked ODs what treatment option they choose first when managing dry eye patients.

View the poll here

A total of 185 responses were tallied. The multiple-choice poll answers included:

• Amniotic membrane
• Artificial tears
• IPL
• Lid therapy
• Meibomian gland device treatments (LipiFlow, BlephEx, iLux, NuLlids)
• Nasal stimulation devices (True Tear)
• Punctal plugs
• Rx drops (Restasis, Xiidra)
• Steroids

Related: Explore the relationship between dry eye and sleep

The majority of respondents look to artificial tears to treat dry eye with 66 percent choosing them first.

Lid therapy was second choice, but the choice was not close. Only 17 percent of respondents look to address the lids first.

After another sharp drop, Rx drops come in third with 8 percent of respondents opting for this therapy to begin treatment.

Related: Ophthalmic community focusing on DED education

Meibomian gland device treatments are fourth with 5 percent of ODs, then steroids and punctal plugs tie for fifth place with 2 percent of respondents.

IPL hits seventh place with only 1 percent of ODs choosing this option first.

Amniotic membrane and nasal stimulation tie for last place with 0 votes for them.

Related: Understanding prevalence, demographics of dry eye disease

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
© 2025 MJH Life Sciences

All rights reserved.